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Abstract
Background: It has been proposed that high insulin levels may cause delayed lung development in the
fetuses of diabetic mothers. A key event in lung development is the production of adequate amounts
of pulmonary surfactant. Insulin inhibits the expression of surfactant protein A (SP-A), the major
surfactant-associated protein, in lung epithelial cells. In the present study, we investigated the signal
transduction pathways involved in insulin inhibition of SP-A gene expression.
Methods: H441 cells, a human lung adenocarcinoma cell line, or human fetal lung explants were
incubated with or without insulin. Transcription run-on assays were used to determine SP-A gene
transcription rates. Northern blot analysis was used to examine the effect of various signal transduction
inhibitors on SP-A gene expression. Immunoblot analysis was used to evaluate the levels and
phosphorylation states of signal transduction protein kinases.
Results: Insulin decreased SP-A gene transcription in human lung epithelial cells within 1 hour. Insulin
did not affect p44/42 mitogen-activated protein kinase (MAPK) phosphorylation and the insulin
inhibition of SP-A mRNA levels was not affected by PD98059, an inhibitor of the p44/42 MAPK
pathway. In contrast, insulin increased p70 S6 kinase Thr389 phosphorylation within 15 minutes.
Wortmannin or LY294002, both inhibitors of phosphatidylinositol 3-kinase (PI 3-kinase), or rapamycin,
an inhibitor of the activation of p70 S6 kinase, a downstream effector in the PI 3-kinase pathway,
abolished or attenuated the insulin-induced inhibition of SP-A mRNA levels.
Conclusion: Insulin inhibition of SP-A gene expression in lung epithelial cells probably occurs via the
rapamycin-sensitive PI 3-kinase signaling pathway.
Keywords: insulin, lung epithelial cells, MAPK, PI 3-kinase, surfactant protein A
Introduction
Fetuses of diabetic mothers with uncontrolled blood glu-
cose levels tend to be hyperglycemic and hyperinsulinemic
[1]. An increased incidence of neonatal respiratory distress
syndrome (RDS) has been observed in infants of diabetic
mothers [1]. RDS is caused by inadequate amounts of pul-
monary surfactant due to delayed lung development [2]. It
has been proposed that high insulin levels can delay lung
development in the fetus of the diabetic mother [3].
Surfactant, a lipoprotein comprised of phospholipids
(~80%), cholesterol (~10%), and proteins (~10%), func-
tions to reduce surface tension and prevents alveolar col-
lapse at end expiration [4]. The surfactant-associated
proteins (SP) A, B, C and D, which are required for proper
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surfactant function, are developmentally and hormonally
regulated [4]. We, and others, have shown that the SP-A
levels in the amniotic fluid of diabetic mothers are signifi-
cantly decreased [1]. Low SP-A levels in amniotic fluid have
been correlated with an increased incidence of neonatal
RDS [5]. Our previous studies have shown that insulin
down-regulates SP-A mRNA and protein levels in human
lung epithelial cells in a concentration and time-dependent
manner via an inhibition of gene transcription [6,7].
Insulin transduces its cellular signal in most cell types via
two signaling pathways, i.e., the p44/42 mitogen-activated
protein kinase (MAPK) pathway and the phosphatidylinosi-
tol 3-kinase (PI 3-kinase) pathway [8]. Insulin initially binds
to the insulin receptor causing autophosphorylation of the
β-subunit of the receptor [8]. The protein kinase domain of
the β-subunit then phosphorylates tyrosine residues in in-
sulin receptor substrate (IRS)-1, IRS-2, IRS-3, or Shc,
which then activates the p44/42 MAPK signaling cascade
[8]. PD98059 is a cell permeable, non-competitive, revers-
ible inhibitor of MAPK/extracellular signal-regulated kinase
kinase (MEK), a protein kinase upstream of p44/42 MAPK
[9]. Tyrosine phosphorylated IRS also activates the PI 3-ki-
nase pathway [8,10]. There are at least three, well-charac-
terized inhibitors of the PI 3-kinase pathway, i.e.,
wortmannin, LY294002, and rapamycin [11–13]. Wort-
mannin and LY294002 block the activation of PI 3-kinase
itself [11,12], while rapamycin prevents the phosphoryla-
tion of a downstream effector in the pathway, p70 S6 ki-
nase [13].
In the present study, we used two experimental models, a
human lung adenocarcinoma cell line, NCI-H441, and hu-
man fetal lung explants. H441 cells resemble bronchiolar
epithelial Clara cells in phenotype and produce both SP-A
and SP-B mRNA and protein [14]. The hormonal regulation
of SP-A and SP-B gene expression in H441 cells is similar
to that observed in differentiated type II cells in human fetal
lung explants [6,7,15,16]. We treated H441 cells with the
four inhibitors of signal transduction: wortmannin,
LY294002, rapamycin and PD98059, to elucidate which
signaling pathways are activated when insulin inhibits SP-
A gene expression. To confirm these results, we repeated
key experiments with insulin and the signal transduction in-
hibitors using human fetal lung explants. We then examined
the levels and phosphorylation state of key enzymes in the
p44/42 MAPK and PI 3-kinase signaling pathways. We
found that insulin probably inhibits SP-A gene expression in
lung epithelial cells via the rapamycin-sensitive PI 3-kinase
pathway.
Materials and methods
Cell and explant cultures
A human lung adenocarcinoma cell line, NCI-H441, was
maintained in vitro in monolayer culture in 10% fetal bovine
serum in the presence of penicillin (100 U/ml), streptomy-
cin (100 µg/ml) and fungizone (0.25 µg/ml) at 37°C in a
5% CO2 atmosphere [14]. Culture media were changed
every 3 days and cells were passed (1:4) weekly. For the
inhibitor experiments, the H441 cells were grown until
~80% confluent, then incubated in serum-free media for 24
hours prior to an experiment. The cultured cells were sub-
sequently exposed to fresh serum-free media and pretreat-
ed for 30–60 minutes with either control media that
contained the vehicle for the inhibitors (dimethyl sulphox-
ide) or with media that contained wortmannin (5–200 nM),
LY294002 (2–50 µM), rapamycin (1–100 nM), or
PD98059 (2.5–25 µM). After pretreatment, either insulin
(2.5 µg/ml) or vehicle (dilute HCl) was added for an addi-
tional 12–16 hours. Experiments were repeated three to
five times unless otherwise noted.
Human lung tissue was obtained from mid-tremester abor-
tuses (15–21 weeks old), dissected free from blood ves-
sels and conducting airways, then minced with a sterile
razor blade into ~1 mm3 explants [6]. The explants were
maintained on lens paper-covered stainless steel grids at
the air-media interface in Waymouth's media at 37°C and
5% CO2 for 6 days. The media were changed daily. On the
last day of culture, explants were pretreated with signal
transduction inhibitors, either wortmannin, rapamycin or
PD98059, for 30–60 min and then further treated with in-
sulin (2.5 µg/ml) for 12–24 hours. Experiments were per-
formed in duplicate and were repeated twice.
Reagents
Porcine insulin was purchased from Calbiochem (San Di-
ego, CA, USA), wortmannin, LY294002, and rapamycin
were purchased from Sigma-Aldrich Company (St. Louis,
MO, USA), and PD98059 was purchased from New Eng-
land Biolabs (Beverly, MA, USA). Insulin was prepared as
2.5 mg/ml stock solution in ~0.01 N HCl, aliquoted and
stored at -80°C. Wortmannin, LY294002, rapamycin and
PD98059 were reconstituted in dimethyl sulphoxide as 1
mM, 50 mM, 50 µM and 10 mM stock solutions, respective-
ly, and stored at -80°C in aliquots. Insulin causes a time-
and dose-dependent inhibition of SP-A gene expression
with maximum effect at 0.25–2.5 µg/ml (~40 to 400 nM)
[7]. In order to achieve a maximal inhibitory effect of insulin,
we used a concentration of 2.5 µg/ml in the present study.
Transcription run-on assay
Nuclear isolation, transcription elongation reactions and hy-
bridizations were performed as described previously with
minor modifications [7]. Subconfluent H441 cells were in-
cubated in serum-free media for 24 hours and then ex-
posed to media plus either vehicle or insulin (2.5 µg/ml) for
an additional 1, 4, 8 and 24 hours. The cells were then
rinsed and trypsinized, and nuclei from control and treated
cells were harvested. The transcription elongation reactionAvailable online http://respiratory-research.com/content/3/1/27
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was performed with 20 × 106 nuclei. Labeled, newly syn-
thesized RNA was then isolated and purified from the nu-
clei. Nytran membranes with immobilized cDNAs for the
BlueScript vector, human SP-A and human α-actin were
prehybridized in 1 ml of buffer (50% formamide, 5 X SSC,
5 X Denhardt's solution, 100 µg/ml denatured herring
sperm, 0.1% SDS) for 4 hours at 45°C and then hybridized
to the labeled RNAs (6 × 106 cpm in the presence of 500
units of RNasin) in duplicate for an additional 60 hours. Af-
terwards, the hybridized membranes were washed twice in
0.2 X SSC with 0.1% SDS at 55°C for 1 hour, once in 2 X
SSC at 55°C for 15 min, once in 2 X SSC with 10 µg/ml
RNase A at 37°C for 30 min and then rinsed twice in 2 X
SSC at room temperature for 15 min. Membranes were ex-
posed to a Storage Phosphor Screen (Molecular Dynam-
ics, San Francisco, CA, USA) for 3–5 days, scanned using
a PhosphorImager (Molecular Dynamics) and data quanti-
tated using Quantity One software (Bio-Rad Laboratories,
Hercules, CA, USA).
Northern blot analysis
Northern blot analysis was used to semi-quantitate SP-A
mRNA levels. H441 cells were harvested and total RNA
isolated as described previously [16]. Equal amounts of to-
tal RNA from each condition were separated on agarose
gels, transferred to Nytran-plus membranes (Schleicher
and Schuell, Keene, NH, USA), and subsequently hybrid-
ized with a radiolabeled human SP-A cDNA. Radioactive
bands were detected using X-ray film after a 1–4 hour ex-
posure with an intensifier screen at -70°C. The relative in-
tensity of the reactive bands was estimated by
densitometry and corrected for RNA loading as described
previously [16].
To perform a northern blot analysis of the human fetal lung
explant samples, 4 µg of total RNA from each condition
were immobilized on Nytran-plus membranes (0.2 µm, Sch-
leicher and Schuell) in triplicate in denaturing solution (66
% formamide, 7.9 % formaldehyde, 26 mM MOPS buffer,
pH 7.0, 1.3 mM EDTA, 0.066 M sodium acetate) using a
slot blot apparatus. The membranes were then processed
for northern blot analysis as described above. In addition,
10 µg of total RNA from each explant sample were separat-
ed on agarose gels to ensure the quality of the RNA sam-
ples and to correct for RNA loading.
Immunoblotting
The total amount and phosphorylation states of p44/42
MAPK and p70 S6 kinase were assessed using immunob-
lot analysis according to the methods described by Sharma
and coworkers [17]. H441 cells were incubated in serum-
free media for 24 hours then exposed to fresh control me-
dia plus either insulin (2.5 µg/ml) or vehicle for 15 min, 30
min, 2 hours or 16 hours. Control and treated cells were
rinsed twice with PBS and then incubated with 1 ml of lysis
buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM ED-
TA, 1 mM EGTA, 1.5 mM MgCl2, 50 mM NaF, 5 mM sodi-
um pyrophosphate, 0.2 mM sodium orthovanadate, 2 µg/ml
aprotinin, 2 µg/ml leupeptin, 10% glycerol, 1% Triton X-
100, 0.5% NP-40, 1 mM phenylmethylsulfonyl fluoride) for
1  h o u r  w i t h  s h a k i n g  a t  4 °C. Equal amounts of protein
lysates from each condition in 1X sample buffer (125 mM
Tris-HCl, pH 6.8, 1% β-mercaptoethanol, 2% SDS, 5%
glycerol, 0.003% bromphenol blue) were separated on 7.5
or 10% polyacrylamide gels and subsequently transferred
to nitrocellulose membranes. Immunoblotting of mem-
branes for phospho-MAPK (extracellular signal-regulated
kinase [Erk]1/2) was performed using a Phospho-MAPK
Antibody Sampler kit (Cell Signaling, Beverly, MA, USA)
according to the manufacturer's instructions. The phospho-
MAPK antibody recognizes dual phosphorylated Erk1 and
Erk2 at Thr202/Tyr204. Total p44/42 MAPK was detected
with rabbit polyclonal anti-MAPK (Erk1) (Santa Cruz Bio-
technology, Inc., Santa Cruz, CA, USA), according to the
manufacturer's instructions. Membranes were then incu-
bated with a secondary antibody, horseradish peroxidase-
conjugated anti-rabbit IgG (1:4000, ICN Biomedical Re-
search Products, Costa Mesa, CA, USA). The reactive
bands were detected using chemiluminescence (ECL, Am-
ersham Pharmacia Biotech, Piscataway, NJ, USA). Immu-
noblotting experiments for the detection of total and
phosphorylated p70 S6 kinase were performed using a
PhosphoPlus p70 S6 Kinase (Thr389, Thr421/Ser424)
Antibody kit according to the manufacturer's instructions
(Cell Signaling).
Lactate dehydrogenase assay
Lactate dehydrogenase (LDH) activity was determined in
cell culture media. Pyruvate conversion into lactate was
measured in 0.2 M Tris-HCl (pH 7.2) buffer in the presence
of sodium pyruvate (0.037 mg/ml, Fisher Scientific, Fair
Lawn, NJ, USA) and the reduced form of β-nicotinamide ad-
enine dinucleotide (0.057 mg/ml, Sigma) at 22°C by meas-
uring absorbance at 340 nm. LDH activity was determined
as the rate of decrease in absorbency per min using a
standard curve for lactate hydrogenase (2–40 mU, L-lactic
dehydrogenase, porcine muscle, Sigma). LDH activity in
the media samples was normalized to controls, which were
made equal to one.
Statistical analysis
All experiments were repeated at least three times unless
otherwise stated. Student's t-test or one-way analysis of
variance (ANOVA) followed by Dunnett's test was used to
estimate the statistical significance of the results [18].
Results
Lactate dehydrogenase assay
LDH activity was measured in media obtained from control
H441 cells and cells treated with the various signal trans-Respiratory Research   Vol 3 No 1   Miakotina et al.
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duction inhibitors. LDH activity was not different from con-
trols in cells treated for 12 to 16 hours with either 200 nM
wortmannin, 5 µM LY294002, 20 nM rapamycin, or 10 µM
PD98059 (data not shown).
Effects of signal transduction inhibitors and insulin on 
SP-A mRNA levels
Wortmannin is a fungal metabolite that is a relatively selec-
tive inhibitor of PI 3-kinase with a half-maximal inhibition
(IC50) less than 5 nM [11]. In the wortmannin experiments,
media were changed every 2 hours for a total of 12 hours
in all of the conditions because wortmannin is unstable in
solution at physiological pH [19]. The shorter incubation
time with insulin in the wortmannin experiments resulted in
a decreased inhibitory effect of insulin, i.e., an ~22% inhibi-
tion of SP-A mRNA levels (Fig. 1A) versus an ~40% inhibi-
tion observed after the 16-hour incubation used in the
experiments with rapamycin and PD98059 (Fig. 1B and
1C). Wortmannin, added alone, did not significantly alter
SP-A mRNA levels at any concentration tested (Fig. 1A).
However wortmannin, at concentrations of 5–200 nM,
abolished the insulin-mediated inhibition of SP-A mRNA
levels at all concentrations tested (5–200 nM, Fig. 1A).
To confirm the inhibitory effect of wortmannin on insulin ac-
tion, a structurally different PI 3-kinase inhibitor, LY294002,
was used. LY294002 is a competitive inhibitor of the PI 3-
kinase ATP-binding site, with an IC50 = 1.4 µM in vitro[12].
LY294002, added alone, decreased SP-A mRNA levels at
concentrations greater than 10 µM (data not shown). How-
ever, 2 µM LY294002 abolished the inhibitory effects of in-
sulin, but did not affect basal SP-A mRNA levels. In the
control group, insulin significantly decreased SP-A mRNA
levels to 57 ± 11% of control levels, however, in presence
of 2 µM LY294002, insulin only decreased SP-A mRNA
levels to 87 ± 15% of control levels versus 99 ± 3% of con-
trol levels in samples treated with LY294002 alone (mean
± SE, n = 4, n indicates the number of independent exper-
iments).
Rapamycin inhibits activation of p70 S6 kinase, a down-
stream effector in the PI 3-kinase signaling pathway [13].
Rapamycin forms a complex with FK506-binding protein
12 and this complex blocks the kinase activity of mTOR
(mammalian target of rapamycin), a kinase upstream of p70
S6 kinase [20]. The IC50 for p70 S6 kinase inhibition by ra-
pamycin is ~0.04–0.4 nM [13]. When added alone at con-
centrations of 1–100 nM, rapamycin did not affect SP-A
mRNA levels (Fig. 1B). However, rapamycin abolished the
insulin-mediated inhibition of SP-A gene expression in a
dose-dependent manner.
To examine whether the p44/42 MAPK pathway mediates
insulin signaling in the H441 cells, PD98059, an inhibitor
of the p44/42 MAPK pathway, was used [9]. PD98059
binds to the dephosphorylated form of MEK and prevents
its activation in vivo with an IC50 of 10 µM [9]. PD98059,
added alone, significantly decreased SP-A mRNA levels in
a dose-dependent manner (Fig. 1C). PD98059 had no ef-
fect on the insulin inhibition of SP-A mRNA levels.
We also treated cultured human fetal lung explants with
wortmannin, rapamycin or PD98059 in the presence or ab-
sence of insulin. Fig. 2 shows that wortmannin (100 nM)
and rapamycin (50 nM) both abolished the insulin-mediat-
ed inhibition of SP-A gene expression. In agreement with
the H441 cells results, PD98059 (2.5–10 µM) had no ef-
fect on the insulin inhibition of SP-A mRNA while decreas-
ing basal SP-A mRNA levels in a dose-dependent manner
when added alone.
Transcription rate of human SP-A
In our previous studies, we have shown that insulin inhibits
the rate of SP-A gene transcription after a 24-hour expo-
sure [7]. In this study, we evaluated the effects of insulin on
the transcription rate of the human SP-A and α-actin genes
at several time-points earlier than those used in our previ-
ous studies. The rate of SP-A gene transcription increased
in a time-dependent manner (Fig. 3). Insulin inhibited hu-
man SP-A gene transcription at every time-point tested,
even as early as after 1 hour of insulin treatment. Insulin did
not decrease human α-actin gene transcription at any time
point.
Phosphorylation-activation of protein kinases
Immunoblot analysis of control and insulin-treated H441
cells using phosphospecific antibodies for p44/42 MAPK
and p70 S6 kinase revealed that both kinases were in a
partially activated state at the 15 min time point. The phos-
phorylation of the protein kinases in the controls declined
over time and remained at minimum levels after 30 min to 2
hours of incubation. We attribute this partial activation of
the signaling kinases to the media change that occurred im-
mediately prior to insulin or vehicle addition [21].
p44/42 MAPK
The total amount of p44/42 MAPK was equal and remained
level in control and insulin-treated cells at all time-points
(Fig. 4A). Insulin did not affect p44/42 MAPK phosphoryla-
tion within a 2-hour incubation time, but significantly de-
creased phosphorylation after 16 hours (Fig. 4B).
Densitometric data of immunoreactive bands of phospho-
p44/42 MAPK in the presence of insulin were equal to 0.39
± 0.01 for the 16 hour time point when compared to the
corresponding controls which were made equal to one
(mean ± SE, t-test, p < 0.05, n = 3).
Since it is possible that the insulin-mediated stimulation of
p44/42 MAPK phosphorylation had ended within a 15 min
exposure to insulin, we performed additional experiments inAvailable online http://respiratory-research.com/content/3/1/27
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order to evaluate the possibility of a shorter time course of
insulin action. Serum-starved cells were incubated with
fresh serum-free media for 1 hour at 37°C (in order to re-
turn the phosphorylation levels of p44/42 MAPK to the ba-
sal state) and then treated with insulin (2.5 µg/ml) or
vehicle for 5 min. Insulin did not activate p44/42 MAPK
within this time frame. The intensity of the immunoreactive
bands of phospho-p44/42 MAPK from insulin-treated cells
was 0.92 ± 0.10 relative to controls, which were made
equal to one (data are the mean of two experiments per-
formed in duplicate plus or minus the standard deviation of
the mean). In order to prove that p44/42 MAPK can be
stimulated in H441 cells by an activator of this kinase, some
cells were also treated with 10 nM 12-O-tetradecanoyl-
phorbol-13-acetate (TPA), a strong stimulator of p44/42
MAPK in H441 cells, for 5 min [21]. TPA caused an approx-
imately twofold increase in p44/42 MAPK phosphorylation
over control levels.
p70 S6 kinase
The total amount of p70 S6 kinase present in the cells de-
creased during the 16 hour incubation period, however,
there was no difference in the amount present in control vs.
insulin-treated cells at any time-point (Fig. 5A). Fig. 5B
shows that despite increased basal p70 S6 kinase phos-
phorylation, insulin caused an additional up-regulation of
p70 S6 kinase on Thr389 after incubation with insulin for
15 min to 16 hours. Phosphorylation of p70 S6 kinase on
Thr389 is essential for the activation of the kinase [22]. In
the presence of insulin, the intensity of the Thr389 p70 S6
kinase bands was significantly increased after 15 min expo-
sure and reached 2.02 ± 0.31 after 15 min and 1.36 ± 0.17
after a 16 hour incubation period when compared to re-
spective controls which were made equal to one (mean ±
SE, t-test, p < 0.05, n = 4). Insulin also stimulated the phos-
phorylation of p70 S6 kinase Thr421/Ser424 at the 30-min
and 2-hour incubation times when compared to their re-
spective controls (Fig. 5C).
Inhibitors of p44/42 MAPK and p70 S6 kinase
PD98059 caused a dramatic decrease in the phosphoryla-
tion of p44/42 MAPK, in the presence or absence of insulin
(Fig. 6A) when compared to controls. Incubation of cells
with rapamycin did not affect p44/42 MAPK phosphoryla-
tion in any condition (Fig. 6B).
Rapamycin completely abolished the phosphorylation of
Thr389 in p70 S6 kinase in insulin-treated cells and also
abolished the basal phosphorylation of p70 S6 kinase in
control cells, at both time points examined (Fig. 6C). Ra-
pamycin also down regulated the Thr421/Ser424 phos-
phorylation in p70 S6 kinase in control and insulin-treated
cells at both time-points (Fig. 6E). PD98059 did not affect
Thr389 or Thr421/Ser424 phosphorylation in p70 S6 ki-
nase in insulin-treated cells at either time point, but slightly
Figure 1
SP-A mRNA levels in the presence or absence of insulin (2.5 µg/ml)
and/or signal transduction inhibitors in H441 cells. SP-A mRNA bands
were analyzed by densitometry and levels in control cells were made
equal to one. Data are presented as the mean ± SE (standard error of
the mean). Asterisks indicate a significant difference when compared to
the control condition (ANOVA, Dunnett's test, p < 0.05 or t-test, p <
0.05), # indicates a significant difference from the insulin alone condi-
tion (ANOVA, Dunnett's test, p < 0.05), n indicates the number of inde-
pendent experiments. (A) Wortmannin, an inhibitor of PI 3-kinase (5–
200 nM), did not affect SP-A mRNA levels at any concentration when
added alone. Wortmannin blocked the inhibitory effect of insulin on SP-
A mRNA at every concentration (n = 4). (B) Rapamycin, an inhibitor of
p70 S6 kinase activation, added alone (1–100 nM), did not affect SP-A
steady-state mRNA levels. Rapamycin blocked the inhibitory effects of
insulin on SP-A gene expression in a dose-dependent manner (n = 3).
(C) PD98059, an inhibitor of p44/42 MAPK (2.5–25 µM), inhibited SP-
A mRNA levels in dose-dependent manner. At 2.5 µM, a concentration
that did not affect basal SP-A mRNA levels, PD98059 did not reverse
the inhibitory effect of insulin (n = 5). ANOVA = analysis of variance;
MAPK = mitogen-activated protein kinase; SP = surfactant proteinRespiratory Research   Vol 3 No 1   Miakotina et al.
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decreased their phosphorylation when added alone (Figs.
6D and 6F).
Discussion
Nothing is known about the relationship between signaling
pathways and the regulation of SP-A gene expression by in-
sulin. In contrast, insulin signal transduction pathways are
well-characterized in a wide variety of cell types [8,10]. In-
sulin is known to primarily transduce its cellular actions via
two signaling pathways, the p44/42 MAPK pathway and
the PI 3-kinase pathway [8,10]. In the present study, we in-
vestigated the signaling pathways that mediate the inhibito-
ry effects of insulin on the expression of the SP-A genes in
human lung epithelial cells.
Figure 2
SP-A mRNA levels in the presence or absence of insulin (2.5 µg/ml)
and/or signal transduction inhibitors in human fetal lung explants.
Explants were grown for 6 days, then treated with inhibitors plus or
minus insulin or vehicle for 12 hours (wortmannin experiments) or 24
hours (rapamycin and PD98059 experiments), harvested and analyzed
for human SP-A mRNA. Data representative of two experiments with
similar results are shown. (A) Wortmannin (100 nM) abolished the insu-
lin-mediated inhibition of SP-A gene expression. (B) Rapamycin (50
nM) inhibited the insulin-mediated decrease in SP-A mRNA level. (C)
PD98059 (2.5–10 µM) decreased basal SP-A mRNA levels in a dose-
dependent manner, but had no effect on the insulin-mediated inhibition
of SP-A gene expression. SP = surfactant protein
Figure 3
Transcription of the human SP-A genes in the presence or absence of
insulin (2.5 µg/ml). The level of transcription in control cells at the 4-
hour time-point was made equal to one. The data are the results of
three experiments expressed as the mean ± SD (standard deviation of
the mean). (A) A representative phospho-image of human SP-A and
human α-actin gene transcription in H441 cells treated with or without
insulin for the time periods indicated. (B) Insulin inhibited human SP-A
gene transcription as early as after 1 hour of insulin exposure, with a
maximum effect observed after 24 hours when compared to controls.
SP = surfactant proteinAvailable online http://respiratory-research.com/content/3/1/27
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Two inhibitors of PI 3-kinase, wortmannin and LY294002,
and an inhibitor of p70 S6 kinase activation, rapamycin,
blocked the inhibitory effect of insulin on SP-A gene ex-
pression. We confirmed these observations by showing
that insulin increased the phosphorylation of a specific ra-
pamycin-sensitive residue (threonine 389), present in the
linker region of p70 S6 kinase, a phosphorylation event that
is known to activate this enzyme [22]. In contrast,
PD98059, an inhibitor of p44/42 MAPK activation, did not
block the inhibitory effects of insulin on SP-A gene expres-
sion. In addition, insulin had no effect on p44/42 MAPK
phosphorylation during a 2-hour incubation. The effects of
the PI 3-kinase and the MAPK pathway inhibitors on SP-A
gene expression were evaluated using two experimental
models, a human immortalized epithelial cell line (H441
cells) and human fetal lung explants. We also demonstrat-
ed that transcriptional inhibition of SP-A gene commences
within 1 hour of exposure to the hormone. Together, our re-
sults are suggestive that insulin activates the rapamycin-
sensitive PI 3-kinase pathway in lung epithelial cells and
that this event leads to an inhibition of SP-A gene transcrip-
tion.
We found that wortmannin and rapamycin had no effect on
basal SP-A mRNA levels, at any concentration tested.
However, PD98059, added alone, abolished p44/42
MAPK phosphorylation in control cells and also inhibited
basal SP-A mRNA levels in a dose-dependent manner. We
hypothesize that a basal level of p44/42 MAPK activity may
be required for SP-A gene expression. Chess and cowork-
ers have shown that transforming growth factor-α and
hepatocyte growth factor increase the phosphorylation of
p44/p42 MAPK in H441 cells [23]. Epidermal growth fac-
tor, which binds to the same receptor as transforming
growth factor-α, increases SP-A content in human fetal
lung [24]. Hepatocyte growth factor has also been shown
to upregulate the synthesis of SP-A in rat type II cells [25].
Thus, phosphorylation of p44/42 MAPK may be involved in
the up-regulation of SP-A gene expression, results consist-
Figure 4
p44/42 MAPK in H441 cells treated with or without insulin (2.5 µg/ml).
Equal amounts of protein homogenate from each condition were sepa-
rated by electrophoresis then probed by immunoblotting. Protein
molecular weight standards (kDa) are shown on the right. The data are
representative of 3 experiments. (A) Total MAPK (p44 and p42,
arrows). The total amount of MAPK was not altered by insulin treatment
at any time-point. (B) Phospho-p44 and p42 MAPK (P-p44 and P-p42,
arrows). Insulin had no effect on the phosphorylation of p44/42 MAPK
when the cells were incubated with insulin for 15 min to 2 hours. After a
16-hour incubation, insulin decreased the levels of phospho-p44/42
MAPK. MAPK = mitogen-activated protein kinase
Figure 5
p70 S6 kinase in H441 cells in the presence or absence of insulin (2.5
µg/ml). Equal amounts of total protein were separated by gel electro-
phoresis and then probed by immunoblot analysis. Protein molecular
weight standards (kDa) are shown on the right. A total lysate of NIH-
3T3 cells treated with serum (L) served as a positive control for p70
S6K detection. The data are representative of four experiments. (A)
Detection of total p70 S6 kinase. The total amount of p70 S6 kinase
declined over time in both the control and insulin-treated conditions
with the least amount of protein detected after a 16-hour incubation.
There was no effect of insulin on the total amount of p70 S6 kinase
when compared to respective control cells at any time point. (B) Detec-
tion of phosphorylated p70 S6 kinase. Insulin increased the phosphor-
ylation of Thr389 in p70 S6 kinase at every time point. (C) Detection of
phospho-p70 S6 kinase. Insulin increased the phosphorylation of
Thr421/Ser424 in p70 S6 kinase after a 30 min and 2 hour incubation
time when compared to controls.Respiratory Research   Vol 3 No 1   Miakotina et al.
Page 8 of 10
(page number not for citation purposes)
ent with our observation that inhibition of basal levels of
p44/42 MAPK phosphorylation may decrease SP-A gene
expression.
In summary, our studies are suggestive that in lung epithe-
lial cells, SP-A gene transcription is inhibited by insulin via
the rapamycin-sensitive PI 3-kinase pathway, but not the
p44/42 MAPK pathway. In cultured human muscle cells,
only the PI 3-kinase – p70 S6 kinase pathway, and not the
MAPK pathway, mediates insulin up-regulation of p85α PI
3-kinase gene expression [26]. Similarly, in L6 myotubes,
insulin induces hexokinase II gene transcription via the ra-
pamycin-sensitive PI 3-kinase pathway, but not via the
MAPK pathway [27]. The PI 3-kinase – p70 S6 kinase
pathway, but not the MAPK pathway, mediates insulin in-
duction of glucose-6-phosphate dehydrogenase gene ex-
pression in primary rat hepatocytes [28]. In H411E liver
cells, insulin down-regulates cAMP-induced phosphoe-
nolpyruvate carboxykinase gene transcription via the PI 3-
kinase pathway, but not via the MAPK pathway [29]. Phos-
Figure 6
p44/42 MAPK and p70 S6 kinase in cells incubated in the presence of insulin (2.5 µg/ml), PD98059 (10 µM) and/or rapamycin (50 nM). Cells were
harvested and immunoblotted for phosphorylated p44/42 MAPK and p70 S6 kinase, then the immunoblots were stripped and reprobed for total
MAPK and p70 S6 kinase. The data are representative of two experiments. Protein molecular weight standards (kDa) are shown on the right. (A)
When the cells were pretreated with PD98059, the phosphorylation of p44/42 MAPK was greatly decreased in both control and insulin-treated cells
after 16 hours. (B) Rapamycin did not affect the phosphorylation of p44/42 MAPK after 16 hours. (C) The phosphorylation of Thr389 in p70 S6
kinase was increased in the presence of insulin after 15 min of incubation and remained increased after 16 hours. Rapamycin abolished the phos-
phorylation of Thr389 in both control and insulin-treated cells at the 15 min and 16-hour incubation times. (D) Insulin increased the phosphorylation
of Thr389 p70 S6 kinase after 15 min and 16-hour incubations. PD98059 did not affect the insulin-induced up-regulation at 15 min. (E) Rapamycin
decreased the phosphorylation of Thr421/Ser424 in p70 S6 kinase after 15 min and 16 hours in control and insulin-treated cells. (F) PD98059
added alone caused a slight decrease in phosphorylation of Thr421/Ser424 p70 S6 kinase in control cells treated for 15 min and 16 hours but did
not affect the phosphorylation in insulin-treated cells. MAPK = mitogen-activated protein kinaseAvailable online http://respiratory-research.com/content/3/1/27
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phorylated p70 S6 kinase has been shown to be present in
the nucleus in insulin-treated cells [30]. Moreover, it has
been shown that p70 S6 kinase phosphorylates and acti-
vates members of the cAMP response element modulator
family of transcription factors [31]. These data raise the
possibility that transcriptional regulation of SP-A gene ex-
pression occurs via the PI 3-kinase – p70 S6 kinase path-
way. Further studies will be required to elucidate the
function of p70 S6 kinase in the nuclear events involved in
SP-A gene transcription.
Conclusion
Our studies are suggestive that insulin inhibits SP-A gene
transcription via the PI 3-kinase pathway in lung epithelial
cells, specifically via the rapamycin-sensitive activation of
p70 S6 kinase. Insulin does not activate p44/42 MAPK and
does not inhibit SP-A gene transcription via the MAPK
pathway. Our findings further characterize the signal trans-
duction pathways that control surfactant protein gene ex-
pression. This information could lead to the possible
modification of these pathways by pharmacological agents
in order to modulate the composition of pulmonary sur-
factant, which is critical for normal respiratory function and
for host defense mechanisms in the lung.
Abbreviations
ANOVA = analysis of variance; Erk= extracellular signal-regulated ki-
nase; IC50 = half-maximal inhibition; IRS = insulin receptor substrate; 
LDH = lactate dehydrogenase; MAPK = mitogen-activated protein ki-
nase; MEK = MAPK/extracellular signal-regulated kinase kinase; mTOR 
= mammalian target of rapamycin; PBS = phosphate-buffered saline; PI 
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